Adoptive immunotherapy with lymphokine‐activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

Saburo Onishi, Toshiji Saibara, Masanao Fujikawa, Hiroshi Sakaeda, Yasushi Matsuura, Yoichi Matsunaga, Yasutake Yamamoto – 1 September 1989 – Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokine‐activated killer cells plus recombinant interleukin 2.

Myeloproliferative disorders in portal vein thrombosis in adults

Tasmin A. Knox, Marshal M. Kaplan – 1 September 1989 – In a prospective study of 33 adults with portal vein thrombosis unrelated to a liver tumor, we have assessed the prevalence of primary myeloproliferative disorders using conventional criteria and cultures of bone marrow progenitor cells. A primary myeloproliferative disorder was documented in 14 patients investigated at the time of recognition of portal vein thrombosis.

Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure

Alastair Forbes, Graeme J. M. Alexander, John G. O'Grady, Richard Keays, Richard Gullan, Sheila Dawling, Roger Williams – 1 September 1989 – Intracranial hypertension complicating fulminant hepatic failure has a mortality in excess of 90% in the presence of renal failure if not rapidly responsive to mannitol and ultrafiltration. Based on data which suggest that barbiturates can be of value in controlling the intracranial hypertension of head injury, intravenous thiopental was assessed in 13 patients with fulminant hepatic failure.

Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices

Rex J. Polson, David Westaby, Alexander E. S. Gimson, Peter C. Hayes, Anthony J. Stellon, Karen Hayllar, Roger Williams – 1 September 1989 – One hundred eighty patients with variceal bleeding and treated by long‐term sclerotherapy were randomized into a prospective randomized controlled clinical trial to assess the efficacy of sucralfate in reducing the frequency of rebleeding from esophageal ulceration prior to variceal obliteration.

Effect of D‐tryptophan‐6‐luteinizing hormone‐releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma

Jérǒme Guéchot, Nicolas Peigney, François Ballet, Michel Vaubourdolle, Jacqueline Giboudeau, Raoul Poupon – 1 September 1989 – Certain evidence suggests androgen dependence of hepatocellular carcinoma in cirrhotic patients. Consequently, it was postulated that antiandrogen therapy might be effective in the treatment of hepatocellular carcinoma. D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone is a potent agonist analog of luteinizing hormone‐releasing hormone which, when chronically administered, inhibits the pituitary gonadal axis and testicular androgen secretion in man.

Hepatitis delta virus infection in French male HBsAg‐positive homosexuals

Stanislas Pol, Frédéric Dubois, Philippe Roingeard, Linda Zignego, Chantal Housset, Christian Brechot, Alain Goudeau, Pierre Berthelot – 1 September 1989 – The prevalence and serological features of hepatitis delta virus infections were studied in a French population of chronic, non‐drug addict, hepatitis B surface antigen carriers: 42 male homosexual patients were compared to 30 nonhomosexuals (20 who evidently had not been exposed to any of the usual hepatitis B virus‐hepatitis delta virus risk factors and 10 hemodialyzed patients or kidney allograft recipients).

Drug‐binding proteins after liver transplantation: Are they significant?

J. Michael Tredger, Roger Williams – 1 September 1989 – In patients with liver disease, the synthesis of drug‐binding proteins may be impaired. After liver transplantation, levels of drug‐binding proteins are unknown. Consequently, concentrations of albumin and α‐acid glycoprotein (AAG) were measured in stable patients after liver transplantation. Albumin levels were decreased from normal (4.5 ± 3 gm per dl) in patients with liver disease before (3.4 ± 0.7) and after transplantation (3.4 ± 0.8).

Increased galactose clearance after liver transplantation: A measure of increased blood flow through the denervated liver?

J. Michael Henderson, William J. Millikan, Michael Hooks, Beverly Noe, Michael H. Kutner, W. Dean Warren – 1 September 1989 – This study measured the liver blood flow‐dependent index of galactose clearance in patients after liver transplantation, to test the hypothesis that liver blood flow is increased in the denervated liver. Eight normal subjects and 16 patients 1 to 8 months after liver transplant were studied. All patients were stable with no evidence of severe rejection at the time of study.

Subscribe to